Clinical trial · Observational
Registry Platform Colorectal Cancer
Clinical Research Platform for Molecular Testing, Treatment, Quality of Life and Outcome of Patients With Metastatic Colorectal Cancer Receiving Systemic Therapy (AZURITE)
NCT04867525CI-TRIAL-00117714AZURITEactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic colorectal cancer, treated in palliative intention in daily routine practice in Germany.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Physician's choice according to patient's needs. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Colorectal Cancer Metastatic
- interventionNames
- Other: Physician's choice according to patient's needs.
Primary outcomes (1)
- measure
- Course of treatment (treatment reality).
- timeFrame
- 3 years per patient.
- description
- Documentation of anamnestic data and therapy sequences.
Secondary outcomes (5)
- measure
- Best Response.
- timeFrame
- 3 years per patient.
- description
- Documentation of response rates per line of treatment.
- measure
- Progression-free survival.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically proven metastatic colorectal cancer (stage IV) at time of inclusion (patients with metastatic disease and potential curative treatment intention are allowed) * Age ≥ 18 years * Planned first systemic therapy for metastatic disease * Signed and dated informed consent form * Patients participating in the PRO module: prior to or at start of first systemic treatment for mCRC * Patients not participating in the PRO module: within four weeks after start of fist systemic therapy for mCRC Exclusion Criteria: * Patient who do not receive any systemic therapy for mCRC * Patients whose metastatic disease was surgically resected prior to inclusion and who start adjuvant chemotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.